| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
INFLAMMATORY BOWEL DISEASE |
production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria
1 Digestive System Research Unit, Hospitals Vall d’Hebron, Autonomous University, Barcelona, Spain
2 Department of Surgery, Hospitals Vall d’Hebron, Autonomous University, Barcelona, Spain
Correspondence to:
Correspondence to:
Dr F Guarner, Digestive System Research Unit, Hospital General Vall d’Hebron, Barcelona 08035, Spain;
fguarnera{at}medynet.com
Background and aims: Tumour necrosis factor 
(TNF-) plays a key role in the pathogenesis of intestinal inflammation in Crohn’s disease. The effect of bacteria on TNF- release by intestinal mucosa was investigated.
Methods: Ileal specimens were obtained at surgery from 10 patients with Crohn’s disease (ileal stricture) and five disease controls undergoing right hemicolectomy (caecal cancer). Mucosal explants from each specimen were cultured for 24 hours with either non-pathogenic Escherichia coli, Lactobacillus casei DN-114001, L bulgaricus LB10, or L crispatus (each study contained blank wells with no bacteria). Tissue and bacterial viability was confirmed by lactate dehydrogenase (LDH) release and culture. Concentrations of TNF- were measured in supernatants and the phenotype of the intestinal lymphocytes was analysed by flow cytometry.
Results: Coculture of mucosa with bacteria did not modify LDH release. Release of TNF- by inflamed Crohn’s disease mucosa was significantly reduced by coculture with L casei or L bulgaricus; changes induced by L crispatus or E coli were not significant. The effect of L casei and L bulgaricus was not prevented by protease inhibitors. Coculture with L casei and L bulgaricus reduced the number of CD4 cells as well as TNF- expression among intraepithelial lymphocytes from Crohn’s disease mucosa. None of the bacteria induced changes in non-inflamed mucosa.
Conclusions: Probiotics interact with immunocompetent cells using the mucosal interface and modulate locally the production of proinflammatory cytokines.
Keywords: cytokines; inflammatory bowel disease; lymphocytes; microflora
Abbreviations: CFU, colony forming units; IEL, intraepithelial lymphocytes; IL, interleukin; LDH, lactate dehydrogenase; LPL, lamina propria lymphocytes; LB broth, Luria Bertani broth; MRS broth, Man-Rogosa-Sharpe broth; TNF-, tumour necrosis factor
This article has been cited by other articles:
|
|
 |
|
  I. Peluso, D. Fina, R. Caruso, C. Stolfi, F. Caprioli, M. C. Fantini, G. Caspani, E. Grossi, L. Di Iorio, F. M. Paone, et al. Lactobacillus paracasei subsp. paracasei B21060 Suppresses Human T-Cell Proliferation Infect. Immun., April 1, 2007; 75(4): 1730 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Vrese and P. R. Marteau Probiotics and Prebiotics: Effects on Diarrhea J. Nutr., March 1, 2007; 137(3): 803S - 811S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Caballero-Franco, K. Keller, C. De Simone, and K. Chadee The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G315 - G322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Angulo, M. Llopis, M. Antolin, M. Gironella, M. Sans, J. R. Malagelada, J. M. Pique, F. Guarner, and J. Panes Lactobacillus casei prevents the upregulation of ICAM-1 expression and leukocyte recruitment in experimental colitis Am J Physiol Gastrointest Liver Physiol, December 1, 2006; 291(6): G1155 - G1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lukas, M. Bortlik, and Z. Maratka What is the origin of ulcerative colitis? Still more questions than answers. Postgrad. Med. J., October 1, 2006; 82(972): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Oozeer, A. Leplingard, D. D. G. Mater, A. Mogenet, R. Michelin, I. Seksek, P. Marteau, J. Dore, J.-L. Bresson, and G. Corthier Survival of Lactobacillus casei in the Human Digestive Tract after Consumption of Fermented Milk Appl. Envir. Microbiol., August 1, 2006; 72(8): 5615 - 5617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Philippe, D Chakass, X Thuru, P Zerbib, A Tsicopoulos, K Geboes, P Bulois, M Breisse, H Vorng, J Gay, et al. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation Gut, June 1, 2006; 55(6): 815 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Kuhbacher, S J Ott, U Helwig, T Mimura, F Rizzello, B Kleessen, P Gionchetti, M Blaut, M Campieri, U R Folsch, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis Gut, June 1, 2006; 55(6): 833 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A-P Bai and Q Ouyang Probiotics and inflammatory bowel diseases. Postgrad. Med. J., June 1, 2006; 82(968): 376 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Carol, N. Borruel, M. Antolin, M. Llopis, F. Casellas, F. Guarner, and J.-R. Malagelada Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease J. Leukoc. Biol., May 1, 2006; 79(5): 917 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Kamiya, L Wang, P Forsythe, G Goettsche, Y Mao, Y Wang, G Tougas, and J Bienenstock Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats Gut, February 1, 2006; 55(2): 191 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-T. Tien, S. E. Girardin, B. Regnault, L. Le Bourhis, M.-A. Dillies, J.-Y. Coppee, R. Bourdet-Sicard, P. J. Sansonetti, and T. Pedron Anti-Inflammatory Effect of Lactobacillus casei on Shigella-Infected Human Intestinal Epithelial Cells J. Immunol., January 15, 2006; 176(2): 1228 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Menard, D. Laharie, C. Asensio, T. Vidal-Martinez, C. Candalh, A. Rullier, F. Zerbib, F. Megraud, T. Matysiak-Budnik, and M. Heyman Bifidobacterium breve and Streptococcus thermophilus Secretion Products Enhance T Helper 1 Immune Response and Intestinal Barrier in Mice Experimental Biology and Medicine, November 1, 2005; 230(10): 749 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Llopis, M Antolin, F Guarner, A Salas, and J-R Malagelada Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid Gut, July 1, 2005; 54(7): 955 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ingrassia, A. Leplingard, and A. Darfeuille-Michaud Lactobacillus casei DN-114 001 Inhibits the Ability of Adherent-Invasive Escherichia coli Isolated from Crohn's Disease Patients To Adhere to and To Invade Intestinal Epithelial Cells Appl. Envir. Microbiol., June 1, 2005; 71(6): 2880 - 2887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rousseaux, B. Lefebvre, L. Dubuquoy, P. Lefebvre, O. Romano, J. Auwerx, D. Metzger, W. Wahli, B. Desvergne, G. C. Naccari, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-{gamma} J. Exp. Med., April 18, 2005; 201(8): 1205 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Oozeer, J. P. Furet, N. Goupil-Feuillerat, J. Anba, J. Mengaud, and G. Corthier Differential Activities of Four Lactobacillus casei Promoters during Bacterial Transit through the Gastrointestinal Tracts of Human-Microbiota-Associated Mice Appl. Envir. Microbiol., March 1, 2005; 71(3): 1356 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Shanahan Physiological Basis for Novel Drug Therapies Used to Treat the Inflammatory Bowel Diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G417 - G421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Pena, A. B. Rogers, Z. Ge, V. Ng, S. Y. Li, J. G. Fox, and J. Versalovic Probiotic Lactobacillus spp. Diminish Helicobacter hepaticus-Induced Inflammatory Bowel Disease in Interleukin-10-Deficient Mice Infect. Immun., February 1, 2005; 73(2): 912 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Furrie, S Macfarlane, A Kennedy, J H Cummings, S V Walsh, D A O'Neil, and G T Macfarlane Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial Gut, February 1, 2005; 54(2): 242 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Oozeer, D. D. G. Mater, N. Goupil-Feuillerat, and G. Corthier Initiation of Protein Synthesis by a Labeled Derivative of the Lactobacillus casei DN-114 001 Strain during Transit from the Stomach to the Cecum in Mice Harboring Human Microbiota Appl. Envir. Microbiol., December 1, 2004; 70(12): 6992 - 6997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Braat, J. van den Brande, E. van Tol, D. Hommes, M. Peppelenbosch, and S. van Deventer Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1618 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ma, P. Forsythe, and J. Bienenstock Live Lactobacillus reuteri Is Essential for the Inhibitory Effect on Tumor Necrosis Factor Alpha-Induced Interleukin-8 Expression Infect. Immun., September 1, 2004; 72(9): 5308 - 5314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H S Gill and F Guarner Probiotics and human health: a clinical perspective Postgrad. Med. J., September 1, 2004; 80(947): 516 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Adolfsson, S. N. Meydani, and R. M Russell Yogurt and gut function Am. J. Clinical Nutrition, August 1, 2004; 80(2): 245 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Menard, C Candalh, J C Bambou, K Terpend, N Cerf-Bensussan, and M Heyman Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport Gut, June 1, 2004; 53(6): 821 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Robinson, L. M. Chamberlain, M. C. Lopez, C. M. Rush, H. Marcotte, R. W. F. Le Page, and J. M. Wells Mucosal and Cellular Immune Responses Elicited by Recombinant Lactococcus lactis Strains Expressing Tetanus Toxin Fragment C Infect. Immun., May 1, 2004; 72(5): 2753 - 2761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Ghosh, D van Heel, and R J Playford Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut, May 1, 2004; 53(5): 620 - 622. [Full Text] [PDF]
|
|
|
|
|
|
B Sheil, J McCarthy, L O'Mahony, M W Bennett, P Ryan, J J Fitzgibbon, B Kiely, J K Collins, and F Shanahan Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis Gut, May 1, 2004; 53(5): 694 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Halper, L.S. Leshin, S.J. Lewis, and W.I. Li Wound Healing and Angiogenic Properties of Supernatants from Lactobacillus Cultures Experimental Biology and Medicine, December 1, 2003; 228(11): 1329 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bourlioux, B. Koletzko, F. Guarner, and V. Braesco The intestine and its microflora are partners for the protection of the host: report on the Danone Symposium "The Intelligent Intestine," held in Paris, June 14, 2002 Am. J. Clinical Nutrition, October 1, 2003; 78(4): 675 - 683. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
